Health Trials

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

ConditionsMyeloproliferative NeoplasmEssential ThrombocythemiaPrimary Myelofibrosis, Prefibrotic StagePrimary Myelofibrosis, Fibrotic Stage
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Angers

About this trial

Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.

Eligibility criteria

Qualifiers

adults (age ≥18 years),

affiliated to the national social security system,

with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,

for which at least one sample is available at the time of diagnosis or before cytoreductive treatment,

Disqualifiers

patient with another active hematological disease or cancer at the time of diagnosis,

person subject to legal protection scheme or incapable of giving consent.

Trial design

Treatments tested in this trial

  • CALR allele burden quantification

Treatment groups

260 Participants
are divided into 1 treatment group

Sponsors and collaborators

University Hospital, Angers

Lead sponsor

Ligue contre le cancer, France

Collaborator

Source ClinicalTrials.gov